Earnings History Data for Alnylam Pharmaceuticals, Inc. (ALNY) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Release Date Time Est. Time Symbol Name Market Cap (M) Rep. EPS Est. EPS Last years EPS SeekingAlpha Headline Price Change Ext. Hours Price Ext. Hours Change 52 Week Range Volume Avg. Volume Ext. Hours Volume Top Mover
28-10-2021 PM 8:00 AM ET
(Oct 28)
ALNY Alnylam Pharmaceuticals, Inc. 23,500 -1.72 -1.51 -2.18 Alnylam Pharmaceuticals EPS misses by $0.27, misses on revenue
[10/28/2021 8:03 AM]
162.03 -29.13 
(-15.24%)
170.00 -21.16 
(-11.07%)
119.29 - 212.00 2,633,973 400,000 16,321
03-08-2021 PM 8:00 AM ET
(Aug 3)
ALNY Alnylam Pharmaceuticals, Inc. 21,030 -1.61 -1.57 -1.56 Alnylam Pharmaceuticals EPS misses by $0.05, beats on revenue; Revenue outlook raised
[8/3/2021 8:04 AM]
178.68 0.72 
(0.40%)
180.03 2.07 
(1.16%)
119.29 - 184.83 615,759 560,000 101
29-04-2021 PM 8:00 AM ET
(Apr 29)
ALNY Alnylam Pharmaceuticals, Inc. 16,770 -1.71 -1.75 -1.62 Alnylam Pharmaceuticals EPS misses by $0.24, beats on revenue
[4/29/2021 8:06 AM]
139.69 -3.84 
(-2.68%)
139.69 0.0 
(0.00%)
119.29 - 178.41 722,722 480,000 6,430
11-02-2021 PM 8:00 AM ET
(Feb 11)
ALNY Alnylam Pharmaceuticals, Inc. 19,190 -2.09 -1.93 -2.47 Alnylam Pharmaceuticals EPS misses by $0.22, beats on revenue
[2/11/2021 8:03 AM]
165.06 0.90 
(0.55%)
157.91 -6.25 
(-3.81%)
84.97 - 178.41 436,625 796,160 267
05-11-2020 PM 8:00 AM ET
(Nov 5)
ALNY Alnylam Pharmaceuticals, Inc. 14,970 -2.18 -1.75 -1.92 Alnylam Pharmaceuticals EPS misses by $0.24, beats on revenue
[11/5/2020 8:03 AM]
137.86 -1.63 
(-1.17%)
137.86 0.0 
(0.00%)
84.97 - 167.33 710,674 546,653 27,054
06-08-2020 PM 8:00 AM ET
(Aug 6)
ALNY Alnylam Pharmaceuticals, Inc. 17,490 -1.56 -1.82 -2.02 Alnylam Pharmaceuticals EPS beats by $0.23, beats on revenue
[8/6/2020 8:03 AM]
142.98 -7.46 
(-4.96%)
150.44 0.0 
(0.00%)
69.11 - 167.33 349,696 492,424 56,465
06-05-2020 PM ALNY Alnylam Pharmaceuticals, Inc. 15,580 -1.62 -1.89 -1.73 Alnylam Pharmaceuticals EPS misses by $0.01, beats on revenue
[5/6/2020 8:03 AM]
141.23 4.60 
(3.37%)
141.83 0.60 
(0.42%)
65.81 - 147.41 682,019 680,067 242